$pe a plus sign (+) inside this box <math>\rightarrow$

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

			Application Number	09/641,034			
TRANSMITTAL FORM (to be used for all correspondence after initial filing)			Filing Date	August 16, 2000			
			First Named Inventor	YONEDA, TOSHIYUKI			
			Group Art Unit	1653 ECH CS.			
			Examiner Name	MAYES, LAURIE A.			
Total Number of Pages in This Submission			Attorney Docket Number	09/641,034 August 16, 2000 YONEDA, TOSHIYUKI 1653 MAYES, LAURIE A. BEAR-006			
ENCLOSURES (check all that apply)							
	Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declaration Extension of Time Requese Express Abandonment Resolution Information Disclosure State Certified Copy of Priority Documents Response to Missing Parts Incomplete Application Response to Missing Parts Incomplete Application Response to Missing under 37 CFR 1.52 of	Ass (for Dra Lica (s) Pet quest Pro Cha Add Ter Rea (s) Parts Remarks	signment Papers r an Application) awing(s) ensing-related Papers sition sition to Convert to a evisional Application wer of Attomey, Revocation ange of Correspondence dress minal Disclaimer quest for Refund , Number of CD(s	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): 1) Return Postcard			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT							
Signing Attorney/Agent (Reg. No.) Signature PAULA A. BORDEN, 42,344 BOZICEVIC, FIELD & PRANCIS LLP							
Date November 24, 2003							

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS

ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

EXPRESS MAIL LABEL NO. EV333998790US



AMENDMENT UNDER 37 C.F.R. §1.116

Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Express Mail No. EV333998790US

Attorney Docket Confirmation No. 3757 First Named Inventor Application Number Filing Date Group Art Unit Examiner Name L.A. Mayes Title BEAR006 3757 T. Yoneda August 16, 2000 Group Art Unit 1653 Examiner Name L.A. Mayes	Mail No. EV3339987 9	Pous PCHOENTER	ENED SOO,
First Named Inventor Application Number O9/641,034 Filing Date Group Art Unit Examiner Name L.A. Mayes Title Integrin binding motif containing	Attorney Docket	BEAR006	
Application Number 09/641,034 Filing Date August 16, 2000 Group Art Unit 1653 Examiner Name L.A. Mayes Title Integrin binding motif containing	Confirmation No.	3757	302
Filing Date August 16, 2000 Group Art Unit 1653 Examiner Name L.A. Mayes Title Integrin binding motif containing	First Named Inventor	T. Yoneda	70
Group Art Unit 1653 Examiner Name L.A. Mayes Title Integrin binding motif containing	Application Number	09/641,034	7
Examiner Name L.A. Mayes Title Integrin binding motif containing	Filing Date	August 16, 2000	
Title Integrin binding motif containing	Group Art Unit	1653	
	Examiner Name	L.A. Mayes	
peptides and methods of treating skeletal diseases	Title	peptides and methods of treating	

Sir:

This amendment is responsive to the Office Action dated August 22, 2003, for which a threemonth period for response was given, making this response due on or before November 22, 2003. November 22, 2003 fell on a Saturday. This amendment is being filed on the next business day following November 22, 2003. Accordingly, this response is timely filed.

In view of the remarks put forth below, reconsideration and allowance are respectfully requested.

12/02/2003 SDENBOB1 00000100 500815 09641034

01 FC:2202 02 FC:2201

36.00 DA 43.00 DA